Mirati Therapeutics Inc (NASDAQ:MRTX) Sees Significant Increase in Short Interest

Share on StockTwits

Mirati Therapeutics Inc (NASDAQ:MRTX) saw a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 5,420,000 shares, a growth of 7.8% from the October 31st total of 5,030,000 shares. Based on an average daily volume of 663,600 shares, the days-to-cover ratio is currently 8.2 days. Approximately 14.0% of the company’s stock are short sold.

Several equities analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st. Cantor Fitzgerald upped their target price on shares of Mirati Therapeutics from $81.00 to $85.00 and gave the company a “neutral” rating in a research note on Tuesday, October 29th. Cowen restated a “buy” rating on shares of Mirati Therapeutics in a research note on Friday, October 18th. BidaskClub cut shares of Mirati Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JPMorgan Chase & Co. cut shares of Mirati Therapeutics from a “neutral” rating to an “underweight” rating and lowered their target price for the company from $101.00 to $85.00 in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $105.67.

Shares of NASDAQ:MRTX traded up $1.33 during trading on Friday, hitting $100.77. The company’s stock had a trading volume of 182,487 shares, compared to its average volume of 624,062. The company has a 50-day moving average of $89.84 and a 200-day moving average of $90.42. Mirati Therapeutics has a 12 month low of $34.39 and a 12 month high of $111.99. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -31.59 and a beta of 2.05.

Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.25) by ($0.13). Mirati Therapeutics had a negative return on equity of 48.60% and a negative net margin of 2,698.66%. The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $0.50 million. On average, equities research analysts forecast that Mirati Therapeutics will post -5.36 EPS for the current year.

In other Mirati Therapeutics news, Director Michael G. Grey sold 3,042 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $102.44, for a total transaction of $311,622.48. Following the transaction, the director now owns 5,298 shares in the company, valued at approximately $542,727.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bruce L. A. Carter sold 3,000 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $94.74, for a total transaction of $284,220.00. Following the transaction, the director now owns 3,000 shares in the company, valued at approximately $284,220. The disclosure for this sale can be found here. Corporate insiders own 4.86% of the company’s stock.

Several large investors have recently modified their holdings of MRTX. Perceptive Advisors LLC lifted its stake in shares of Mirati Therapeutics by 149.0% in the 2nd quarter. Perceptive Advisors LLC now owns 2,899,606 shares of the biotechnology company’s stock worth $298,659,000 after purchasing an additional 1,735,224 shares during the period. Vanguard Group Inc. lifted its stake in shares of Mirati Therapeutics by 36.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,984,506 shares of the biotechnology company’s stock worth $307,404,000 after purchasing an additional 802,468 shares during the period. Invesco Ltd. lifted its stake in shares of Mirati Therapeutics by 329.7% in the 2nd quarter. Invesco Ltd. now owns 1,002,795 shares of the biotechnology company’s stock worth $103,288,000 after purchasing an additional 769,429 shares during the period. Orbimed Advisors LLC bought a new position in shares of Mirati Therapeutics in the 3rd quarter worth approximately $41,693,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Mirati Therapeutics by 792.6% in the 2nd quarter. Renaissance Technologies LLC now owns 449,000 shares of the biotechnology company’s stock worth $46,247,000 after purchasing an additional 398,700 shares during the period.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers.

Featured Story: What is a Roth IRA?

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Commerzbank Aktiengesellschaft FI Raises Stock Holdings in Walt Disney Co
Commerzbank Aktiengesellschaft FI Raises Stock Holdings in Walt Disney Co
Tocqueville Asset Management L.P. Decreases Stake in Euronet Worldwide, Inc.
Tocqueville Asset Management L.P. Decreases Stake in Euronet Worldwide, Inc.
State of Alaska Department of Revenue Sells 3,892 Shares of Exelixis, Inc.
State of Alaska Department of Revenue Sells 3,892 Shares of Exelixis, Inc.
State of Alaska Department of Revenue Trims Position in Healthequity Inc
State of Alaska Department of Revenue Trims Position in Healthequity Inc
State of Alaska Department of Revenue Grows Stock Holdings in Chatham Lodging Trust
State of Alaska Department of Revenue Grows Stock Holdings in Chatham Lodging Trust
State of Alaska Department of Revenue Lowers Stock Holdings in News Corp
State of Alaska Department of Revenue Lowers Stock Holdings in News Corp


 
© 2006-2020 Zolmax.